Orasure Technologies OSUR
- Market cap
- $284.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $112.4M
- −19% on a year ago
- Net margin
- −43.7%
- Free cash flow yield
- −16.9%
Orasure Technologies trades at 2.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $112.4M over the last twelve months, down 19% on a year earlier with a −44% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $89.2M−23% | $75.9M−38% | $54.1M−65% | $54.3M−36% | $39.9M−55% | $37.4M−51% | $29.9M−45% | $31.2M−43% | $27.1M−32% | $26.8M−29% | $27.9M−7% | $30.6M−2% | |
| Cost of revenue | $44.8M−36% | $40.8M−44% | $30.1M−66% | $29.6M−50% | $22.8M−49% | $23.9M−41% | $17.6M−41% | $18.1M−39% | $15.3M−33% | $15.8M−34% | $16.1M−9% | $17.3M−4% |
| Gross profit | $44.3M−5% | $35.1M−30% | $24.1M−63% | $24.7M−6% | $17.1M−62% | $13.6M−61% | $12.3M−49% | $13.2M−47% | $11.8M−31% | $11M−19% | $11.8M−4% | $13.3M+1% |
| R&D | $8.5M−16% | $7M−13% | $7.7M−27% | $6.6M−14% | $5.6M−34% | $6.1M−13% | $9.6M+24% | $11.4M+73% | $10.1M+80% | $11.4M+88% | $13.7M+42% | $9.4M−17% |
| SG&A | $18.8M−35% | $20.9M−23% | $20.1M−33% | $19.8M−21% | $17.4M−7% | $19.9M−5% | $21M+4% | $19.1M−4% | $17.4M−0% | $16.4M−18% | $21.3M+2% | $21M+10% |
| $10.9M+1158% | $3.9M−73% | −$7.1M | −$2.7M−57% | −$6M | −$12.4M | −$17.8M+150% | −$18M+558% | −$16.1M+168% | −$20.1M+62% | −$23.3M+31% | $5.4M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $13.5M+203% | $20.7M+33% | −$3.6M | $326K | −$3.2M | −$9.5M | −$16M+343% | −$16.9M | −$13.3M+313% | −$18.4M+94% | −$21.7M+36% | $6.8M |
| $2.3M | $647K | −$18K−92% | $381K | $678K−71% | $758K+17% | −$456K+2433% | $2M+425% | $47K−93% | $210K−72% | −$432K−5% | $55K−97% | |
| Net income | $11.2M+99% | $20.1M+27% | −$3.6M | −$615K−87% | −$4.5M | −$10.8M | −$16M+348% | −$19.7M+3102% | −$13.7M+204% | −$19.3M+79% | −$22.4M+40% | $6.2M |
| $0.15+88% | $0.27+23% | −$0.05 | −$0.01−86% | −$0.06 | −$0.14 | −$0.21+320% | −$0.26+2500% | −$0.19+217% | −$0.27+93% | −$0.32+52% | $0.09 | |
| 74.3M+2% | 75M+3% | 73.9M+0% | 74.2M+1% | 74.6M+0% | 74.7M−0% | 74.9M+1% | 74.5M+1% | 73M−2% | 71.6M−4% | 69.7M−7% | 70.2M−6% |
EPS, diluted: 8 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 10 periods, Q4 FY11 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Orasure Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OSUROrasure Technologies | $284.8M | n/m | 28.9× | 2.5× | −19% | −43.7% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| Peer median | $457.8M | 22.3× | 21.0× | 1.8× | +5% | 6.5% |
More on Orasure Technologies
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .